Luye Pharma Signs a Distribution Agreement with Zuellig Pharma

Luye Pharma Group has announced that it has signed an agreement with Zuellig Pharma, which will give the latter exclusive rights to distribute its central nervous system drugs Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation) in Malaysia and Brunei.

“We are very pleased to collaborate with Zuellig Pharma again. By leveraging its business network and channel resources together with Luye Pharma’s in-house sales and marketing capabilities, we believe the distribution partnership will help better improve the accessibility of Seroquel products for patients in these two markets,” said Andy Siow, APAC Regional Director of Luye Pharma (International). “Meanwhile, we are also looking forward to working with more business partners, integrating resources from all sides to bring more high-quality and evidence-based innovative drugs to benefit patients in need.”

Luye Pharma has been continuously working to improve business capabilities around the globe and exploring growth opportunities. In Asia Pacific, Luye Pharma’s business footprint covers 15 countries and regions, with the company continuing to further expand in various markets through the establishment of its in-house sales and marketing team in Malaysia, Brunei, Singapore, Australia, Hong Kong SAR, and Taiwan, China, as well as in other markets, through in-depth collaborations with a number of global partners in the region.